News Headlines Article

Pfizer guts it out in obesity, diabetes deal with Second Genome
San Francisco Business Times

Pfizer Inc., with the help of South San Francisco’s Second Genome, wants to peer into the gut to discover how the cast of bacterial characters there plays a role in obesity and diabetes. The companies said Friday they will work with Massachusetts General Hospital to study the microbiome — the community of trillions of bacteria in the gut — of about 900 people. Specifically, the study will look at obese people with type 2 diabetes and those who have not been diagnosed with the condition.